[{"id":"0d8f1ed3-a22c-48e1-aa44-43808dd8c739","acronym":"","url":"https://clinicaltrials.gov/study/NCT04595747","created_at":"2021-01-19T20:29:57.852Z","updated_at":"2025-02-25T16:53:20.251Z","phase":"Phase 2","brief_title":"Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)","source_id_and_acronym":"NCT04595747","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FGFR","pipe":"","alterations":" ","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e rogaratinib (BAY 1163877)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 05/03/2021","start_date":" 05/03/2021","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2025-02-04"},{"id":"759e154d-a581-4024-8743-5e57712e180e","acronym":"ROGABREAST","url":"https://clinicaltrials.gov/study/NCT04483505","created_at":"2021-01-18T21:31:39.803Z","updated_at":"2025-02-25T17:24:44.854Z","phase":"Phase 1","brief_title":"Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.","source_id_and_acronym":"NCT04483505 - ROGABREAST","lead_sponsor":"Fundacion CRIS de Investigación para Vencer el Cáncer","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • fulvestrant • rogaratinib (BAY 1163877)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 11/25/2020","start_date":" 11/25/2020","primary_txt":" Primary completion: 04/04/2023","primary_completion_date":" 04/04/2023","study_txt":" Completion: 04/04/2023","study_completion_date":" 04/04/2023","last_update_posted":"2023-12-28"},{"id":"e5913600-1859-40be-b59a-287e730ac963","acronym":"","url":"https://clinicaltrials.gov/study/NCT04077255","created_at":"2021-01-18T19:58:01.930Z","updated_at":"2024-07-02T16:35:59.842Z","phase":"Phase 2","brief_title":"EGFR-targeted Therapy for Gastric Cancer","source_id_and_acronym":"NCT04077255","lead_sponsor":"National Cancer Center, Korea","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR amplification","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • rogaratinib (BAY 1163877) • GC-1118A"],"overall_status":"Recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 09/01/2019","start_date":" 09/01/2019","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2022-11-30"},{"id":"deb2fc8c-66a8-4c75-a0b4-063ece188bfd","acronym":"ROCOCO","url":"https://clinicaltrials.gov/study/NCT03517956","created_at":"2021-01-18T17:18:57.717Z","updated_at":"2025-02-25T17:10:20.644Z","phase":"Phase 1","brief_title":"Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT03517956 - ROCOCO","lead_sponsor":"Bayer","biomarkers":" FGFR","pipe":"","alterations":" ","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aliqopa (copanlisib) • rogaratinib (BAY 1163877)"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 07/25/2018","start_date":" 07/25/2018","primary_txt":" Primary completion: 02/01/2021","primary_completion_date":" 02/01/2021","study_txt":" Completion: 02/01/2021","study_completion_date":" 02/01/2021","last_update_posted":"2022-07-14"},{"id":"75de18f5-155e-45d7-85e4-d37abf65ca4a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01976741","created_at":"2021-03-02T12:23:56.095Z","updated_at":"2025-02-25T17:07:13.668Z","phase":"Phase 1","brief_title":"Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)","source_id_and_acronym":"NCT01976741","lead_sponsor":"Bayer","biomarkers":" FGF23","pipe":" | ","alterations":" FGFR mutation","tags":["FGF23"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e rogaratinib (BAY 1163877)"],"overall_status":"Completed","enrollment":" Enrollment 168","initiation":"Initiation: 12/30/2013","start_date":" 12/30/2013","primary_txt":" Primary completion: 03/11/2019","primary_completion_date":" 03/11/2019","study_txt":" Completion: 01/09/2020","study_completion_date":" 01/09/2020","last_update_posted":"2021-05-06"},{"id":"d59f7b11-7111-4ed8-aa03-7fac168afde2","acronym":"","url":"https://clinicaltrials.gov/study/NCT02592785","created_at":"2021-01-17T17:39:10.660Z","updated_at":"2025-02-25T17:08:27.420Z","phase":"Phase 1","brief_title":"Phase I Dose Escalation Study of BAY 1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT02592785","lead_sponsor":"Bayer","biomarkers":" FGFR1 • FGF23","pipe":" | ","alterations":" FGFR3 mutation","tags":["FGFR1 • FGF23"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e rogaratinib (BAY 1163877)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 12/15/2015","start_date":" 12/15/2015","primary_txt":" Primary completion: 02/05/2017","primary_completion_date":" 02/05/2017","study_txt":" Completion: 12/06/2017","study_completion_date":" 12/06/2017","last_update_posted":"2018-04-18"}]